Irbesartan content determination is a core analytical test used to verify the potency and batch-to-batch consistency of this widely prescribed angiotensin II receptor blocker in both active pharmaceutical ingredients (API) and finished dosage forms. This technical guide outlines the pharmacopoeial HPLC assay methods, applicable standards such as ChP, USP, Ph. Eur. and BP, sample types, testing items, method validation requirements, and the role of accredited third-party laboratories in ensuring regulatory compliance. Read on to understand how accurate irbesartan quantification supports GMP batch release, stability evaluation, and bioequivalence studies.
Technical Overview
Irbesartan is a potent, selective angiotensin II type 1 (AT1) receptor antagonist used for the treatment of essential hypertension and diabetic nephropathy in patients with type 2 diabetes mellitus. Chemically, it is a spirocyclic imidazolinone derivative bearing a biphenyl tetrazole moiety, with the molecular formula C25H28N6O and a molecular weight of 428.53 g/mol (CAS 138402-11-6).
Content determination (assay) is the quantitative test that establishes the actual amount of irbesartan present in a sample, expressed either as a percentage purity for the API or as a percentage of the labeled amount for finished products such as tablets and capsules. The assay result is a decisive factor for GMP batch release, shelf-life assignment, and regulatory acceptance of a pharmaceutical product. Reversed-phase high-performance liquid chromatography (RP-HPLC) with UV detection is the reference technique, as specified in the major pharmacopoeias including the Chinese Pharmacopoeia (ChP 2020), the United States Pharmacopeia (USP-NF), the European Pharmacopoeia (Ph. Eur.), and the British Pharmacopoeia (BP).
Accredited third-party laboratories performing irbesartan content determination typically operate under an ISO/IEC 17025 quality management system and validate or verify their methods in accordance with ICH Q2 guidelines and USP general chapter requirements to guarantee data integrity and comparability.
Testing Samples
Active Pharmaceutical Ingredient (API)
Bulk irbesartan drug substance, synthetic intermediates, and starting materials submitted by manufacturers for identity confirmation, purity assignment, and release testing. API assay is usually performed on an anhydrous and solvent-free basis, paired with tests for water content and residual solvents.
Finished Dosage Forms
Irbesartan tablets (commonly 75 mg, 150 mg, and 300 mg strengths), capsules, dispersible tablets, and granules. For solid oral dosage forms, the content determination is conducted on a composite of multiple units to obtain a representative average content, complemented by content uniformity testing of individual units.
Fixed-Dose Combination Products
Combination preparations containing irbesartan together with hydrochlorothiazide or amlodipine. Validated chromatographic methods must resolve all active components simultaneously so that each ingredient can be quantified from a single sample preparation.
Stability and Research Samples
Samples drawn from accelerated and long-term stability chambers under ICH Q1A conditions, clinical trial supplies, reference batches for bioequivalence studies, and process development or formulation research specimens.
Testing Items
The content determination portfolio for irbesartan typically covers the following quantitative items:
- Assay of irbesartan API: purity determination, generally required to fall within 98.0% to 102.0% calculated on the anhydrous basis, as defined by the applicable monograph.
- Assay of tablets and capsules: content expressed as a percentage of the labeled amount, with a typical acceptance range of 95.0% to 105.0%.
- Content uniformity: determination of individual unit doses (usually 10 units) to demonstrate uniformity of dosage units in accordance with pharmacopoeial requirements.
- Dissolution testing with quantification: measurement of irbesartan released from the dosage form at specified time points, commonly using paddle apparatus with 900 mL of dissolution medium, with the dissolved amount quantified by the same validated HPLC method.
- Supporting determinations closely associated with assay: related substances (degradation products and process impurities), water determination, and residual solvents, which are needed to calculate and interpret the assay on a corrected basis.
Testing Methods
Reversed-Phase HPLC with UV Detection (Primary Method)
The compendial assay is based on reversed-phase HPLC using an external standard method against a certified irbesartan reference standard. Representative chromatographic conditions are:
- Column: C18 reversed-phase column, 250 mm × 4.6 mm, 5 μm particle size (equivalent columns permitted after system suitability verification).
- Mobile phase: binary system of phosphate buffer (potassium dihydrogen phosphate adjusted with phosphoric acid to approximately pH 3.0) and acetonitrile, typically in the proportion range of 55:45 to 60:40 (v/v).
- Flow rate: approximately 1.0 mL/min; column temperature maintained at 25 °C to 35 °C.
- Detection: UV wavelength commonly set between 220 nm and 254 nm, with the exact value specified by the individual monograph and verified during method suitability.
- Injection volume: 10 to 20 μL; quantification by comparing the peak area of the sample solution with that of the standard solution.
System suitability criteria generally require a tailing factor of not more than 2.0, a theoretical plate count of not less than 2000, and a relative standard deviation of replicate standard injections of not more than 2.0%.
Sample Preparation
For tablets, not fewer than 20 units are weighed and finely powdered; an accurately weighed portion of the powder equivalent to a target quantity of irbesartan is extracted with the diluent (mobile phase, methanol, or a methanol-water mixture) with the aid of ultrasonication. The resulting solution is diluted to volume, centrifuged if necessary, and filtered through a 0.45 μm membrane filter before injection. API samples are dissolved directly in a suitable solvent and diluted to the working concentration.
UHPLC Method
Ultra-high-performance liquid chromatography using sub-2 μm particles achieves equivalent separations with significantly shorter run times and reduced solvent consumption, and is increasingly adopted for high-throughput routine quality control after full method equivalence verification.
UV Spectrophotometry
Spectrophotometric quantification at the absorption maximum of irbesartan offers a simple and economical alternative for routine in-process checks and tablet assay in matrices demonstrated to be free of spectral interference, although HPLC remains the preferred confirmatory technique.
LC-MS/MS for Biological Matrices
For pharmacokinetic and bioequivalence studies, irbesartan in human or animal plasma is quantified by liquid chromatography coupled with tandem mass spectrometry, achieving sensitivity in the low nanogram-per-milliliter range with high selectivity.
Method Validation and Verification
Non-compendial or modified methods are validated in accordance with ICH Q2 and USP general chapters, covering specificity, linearity (correlation coefficient typically not less than 0.999 across 80% to 120% of the working concentration), accuracy (mean recovery usually within 98.0% to 102.0%), precision (intra-day and inter-day RSD not more than 2.0%), range, robustness, and solution stability.
Applications
GMP Batch Release and Quality Control
Content determination is a mandatory release test for every commercial batch of irbesartan API and finished products, providing documented evidence that the product conforms to its registered specification.
Stability Studies
Assay data generated at defined intervals under ICH long-term, intermediate, and accelerated conditions support shelf-life determination and the evaluation of degradation trends.
Supplier Verification and Incoming Material Control
Pharmaceutical manufacturers rely on independent assay results to verify the quality of purchased irbesartan API and excipients before use in production.
Bioequivalence and Clinical Research
Quantitative data on dosage form content underpin the design and credibility of bioequivalence trials and clinical supply manufacturing.
Regulatory Submission Support
Complete, validated assay documentation forms part of the quality dossier for marketing authorization applications, variations, and pharmacopoeial compliance declarations.
FAQ
Which standards govern irbesartan content determination?
The principal references are the monographs for irbesartan and its dosage forms in the Chinese Pharmacopoeia (ChP 2020), the United States Pharmacopeia (USP-NF), the European Pharmacopoeia (Ph. Eur.), and the British Pharmacopoeia (BP), supplemented by ICH Q2 for method validation and ISO/IEC 17025 for laboratory competence.
What are the typical acceptance criteria for the assay?
For the API, content is generally required to be within 98.0% to 102.0% calculated on the anhydrous basis, while tablets and capsules are typically expected to contain between 95.0% and 105.0% of the labeled amount. The exact limits must always be taken from the specific monograph or registered specification.
How much sample is required for testing?
For an API assay, approximately 200 to 500 mg of representative material is usually sufficient. For tablet assay and content uniformity, a minimum of 20 dosage units is recommended. Additional quantities are needed if related substances, dissolution, or repeat determinations are requested.
What is the typical turnaround time?
Standard HPLC content determination at an accredited third-party laboratory is generally completed within 5 to 10 working days after sample receipt, with expedited services available for urgent quality investigations.
Can combination products such as irbesartan and hydrochlorothiazide tablets be tested?
Yes. Validated HPLC methods can resolve and quantify both actives from a single sample preparation, with system suitability demonstrating adequate resolution between the two components and any interfering peaks.
Is method validation necessary if a non-compendial method is used?
Yes. Any in-house or modified method must be fully validated for specificity, linearity, accuracy, precision, range, robustness, and solution stability in accordance with ICH Q2 before it can be used for release or stability decisions.
